Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
November 21st 2017
Prima BioMed Changes its Name to Immutep Ltd
November 21st 2017
FAQ - Change of company name from 'Prima BioMed Limited' to 'Immutep Limited'
November 18th 2017
Chairman’s Address 2017 Annual General Meeting
November 18th 2017
Results of Annual General Meeting
November 18th 2017
Annual General Meeting CEO Presentation
November 16th 2017
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
November 10th 2017
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
November 2nd 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
October 21st 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
October 18th 2017
Notice of Annual General Meeting/Proxy Form
October 18th 2017
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
September 9th 2017
Prima Secures Japanese Patent Grant for IMP731 Antibody
September 6th 2017
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
August 31st 2017
Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
August 22nd 2017
Prima BioMed Appoints Non-Executive Director to the Board
August 22nd 2017
Appendix 3X
August 8th 2017
Appendix 3B
August 8th 2017
Appendix 3Y
August 7th 2017
Prima BioMed Receives A$1.3 Million Tax Refund from French Government
July 19th 2017
Financial Update 2H17
July 18th 2017
Prima BioMed Announces Second Milestone Payment for IMP701 Program
July 11th 2017
Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
July 7th 2017
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
July 7th 2017
Cleansing Notice
July 5th 2017
Appendix 3B – US$5m Capital Raising
July 4th 2017
Final Prospectus Supplement
July 1st 2017
Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares
June 27th 2017
Operational Update
June 6th 2017
LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
June 6th 2017
ASCO Poster 2017
June 2nd 2017
Prima BioMed Announces Formation of Clinical Advisory Board
May 19th 2017
Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
April 20th 2017
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
April 13th 2017
Prima BioMed receives A$492,144 Tax Refund from Australian Government
March 16th 2017
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
March 2nd 2017
USA Patent Grants for IMP321 in Cancer
February 25th 2017
First Half 2017 Operational Update
February 14th 2017
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
January 24th 2017
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
January 21st 2017
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
January 19th 2017
Prima BioMed to Maintain NASDAQ Listing
January 13th 2017
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
January 6th 2017
Prima BioMed enters new Material Transfer Agreement with Cytlimic
January 3rd 2017
Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy
